Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition (HI-SPEED)
Implementation of a Stroke Protocol for Emergency Evaluation and Disposition
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Shyam Prabhakaran, MD, MS
- Phone Number: 773-702-0080
- Email: shyam1@bsd.uchicago.edu
Study Contact Backup
- Name: Jane L Holl, MD, MPH
- Phone Number: 773-702-8186
- Email: jholl@bsd.uchicago.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Yale New Haven Hospital
-
Contact:
- Joseph Schindler, MD
- Phone Number: 203-737-1057
- Email: joseph.schindler@yale.edu
-
Principal Investigator:
- Joseph Schindler, MD
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- Jackson Memorial Hospital
-
Contact:
- Gillian Gordon Perue, MD
- Phone Number: 786-466-1380
- Email: ggordonperue@miami.edu
-
Principal Investigator:
- Gillian Gordon Perue, MD
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University Hospital
-
Contact:
- Fadi Nahab, MD
- Email: fnahab@emory.edu
-
Principal Investigator:
- Fadi Nahab, MD
-
-
Illinois
-
Chicago, Illinois, United States, 60426
- Recruiting
- UChicago Medicine Ingalls Memorial Hospital
-
Contact:
- Lakshmi Warrior, MD
- Phone Number: 203-737-1057
- Email: Lakshmi.Warrior@bsd.uchicago.edu
-
Principal Investigator:
- Lakshmi Warrior, MD
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan Hospital
-
Contact:
- Will Meurer, MD, MS
- Email: wmeurer@umich.edu
-
Principal Investigator:
- Will Meurer, MD, MS
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- New York Presbyterian - Weill Cornell Hospital
-
Principal Investigator:
- Ava L Liberman, MD
-
Contact:
- Ava L Liberman, MD
- Email: all9188@med.cornell.edu
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Recruiting
- University of Cincinnati Medical Center
-
Contact:
- Christopher T Richards, MD, MS
- Phone Number: 513-585-8962
- Email: richa2ch@ucmail.uc.edu
-
Principal Investigator:
- Christopher T Richards, MD, MS
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Recruiting
- University of Utah Health
-
Principal Investigator:
- Lee S Chung, MD
-
Contact:
- Lee S Chung, MD
- Email: lee.chung@hsc.utah.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >=18 years
- Final diagnosis: AIS, ICH, or SAH
Exclusion Criteria:
- Final diagnosis: TIA or stroke NOS
- Age <18 years
- Comfort care measures on day 0 or 1
- Left hospital against medical advice
- Enrolled in clinical trial related to stroke that is competing with this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control Phase
Pre-implementation of HI-SPEED Protocol
|
|
|
Active Comparator: Implementation Phase
Post-Implementation of HI-SPEED Protocol
|
The HI-SPEED Protocol or Bundle consists of 7 components including 1) stroke screening scales, 2) imaging pathways, 3) telestroke operations, 4) a best practice alert, 5) stroke team communication tool, 6) door-to-needle (thrombolysis) treatment pathway, and 7) a standardized hand-off tool.
This protocol will be implemented at each participating health system in clusters of 2 health systems.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
DIDO time in acute ischemic stroke patients
Time Frame: Baseline
|
Time from ED arrival to ED departure prior to transfer to a comprehensive stroke center among ischemic stroke patients
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
DIDO time in acute hemorrhagic stroke patients
Time Frame: Baseline
|
Time from ED arrival to ED departure prior to transfer to a comprehensive stroke center among hemorrhagic stroke patients
|
Baseline
|
|
Modified Rankin Scale score at 3 months in acute ischemic stroke patients undergoing endovascular therapy
Time Frame: 3 months post-stroke
|
Proportion of acute ischemic stroke patients who undergo endovascular therapy and achieve good functional outcome (mRS 0-2) at 3 months post-stroke
|
3 months post-stroke
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Shyam Prabhakaran, MD, MS, University of Chicago
- Principal Investigator: Jane Holl, MD, MPH, University of Chicago
Publications and helpful links
General Publications
- Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812.
- Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, Olson DM, Hernandez AF, Peterson ED, Schwamm LH. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013 Jun 19;309(23):2480-8. doi: 10.1001/jama.2013.6959.
- Anderson CS, Chalmers J, Stapf C. Blood-pressure lowering in acute intracerebral hemorrhage. N Engl J Med. 2013 Sep 26;369(13):1274-5. doi: 10.1056/NEJMc1309586. No abstract available.
- Richards CT, Holl JL, Khorzad R, Prabhakaran S. Abstract TMP70: Simulation Modeling Predicts Actual Patient Transport Rates Following the Implementation of a Prehospital Comprehensive Stroke Center DirectTransport Protocol. Stroke. 2020;51(Suppl_1):ATMP70-ATMP70.
- Menon BK, Saver JL, Goyal M, Nogueira R, Prabhakaran S, Liang L, Xian Y, Hernandez AF, Fonarow GC, Schwamm L, Smith EE. Trends in endovascular therapy and clinical outcomes within the nationwide Get With The Guidelines-Stroke registry. Stroke. 2015 Apr;46(4):989-95. doi: 10.1161/STROKEAHA.114.007542. Epub 2015 Feb 13.
- Mendelson SJ, Aggarwal NT, Richards C, O'Neill K, Holl JL, Prabhakaran S. Racial disparities in refusal of stroke thrombolysis in Chicago. Neurology. 2018 Jan 30;90(5):e359-e364. doi: 10.1212/WNL.0000000000004905. Epub 2018 Jan 3.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Ischemic Stroke
- Hemorrhagic Stroke
- Stroke
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Agents
- Membrane Transport Modulators
- Adrenergic Agents
- Central Nervous System Stimulants
- Dopamine Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Dopamine Agents
- Adrenergic Uptake Inhibitors
- Sympathomimetics
- Methamphetamine
Other Study ID Numbers
Other Study ID Numbers
- IRB22-1932
- 1U01NS131797-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.